Licensing
TcLand Expression of Nantes, France, a specialist in biomarkers and companion diagnostics for use in immune system disorders, has entered a strategic partnership with the Hospital Vall d'Hebron Research Institute (VHIR) in Barcelona, Spain, for the development of biomarkers for predicting responses to anti-TNF alpha inhibitors in treating rheumatoid arthritis.
The partnership is founded on the expertise of rheumatologist Sara Marsal, Director of the Grup de Recerca de Reumatologia at VHIR. TcLand Expression says the deal will strengthen its commercial position in the field of biomarkers for autoimmune diseases.
“Personalised medicine is becoming a reality in many diseases, including autoimmune disorders like rheumatoid arthritis. New genomics tools are empowering us to discover molecular patterns that are associated with pathological processes and, in some cases, can be useful predictive tools,” Marsal said.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
